Evaluating the accuracy of technicians and pharmacists in checking unit dose medication cassettes

2002 ◽  
Vol 59 (12) ◽  
pp. 1183-1188 ◽  
Author(s):  
Peter J. Ambrose ◽  
Frank G. Saya ◽  
Larry T. Lovett ◽  
Sandy Tan ◽  
Dale W. Adams ◽  
...  
Keyword(s):  
2000 ◽  
Vol 35 (2) ◽  
pp. 169-175 ◽  
Author(s):  
Robert A. Quercia ◽  
Ronald Abrahams ◽  
C. Michael White ◽  
John D'Avella ◽  
Mary Campbell

A pharmacy-managed anemia program included distribution and clinical components, with the goal of making epoetin alpha therapy for hemodialysis patients more cost-effective. The Pharmacy Department prepared epoetin alpha doses for patients in unit-dose syringes, utilizing and documenting vial overfill. Pharmacists dosed epoetin alpha and iron (oral and intravenous) per protocol for new and established patients. Baseline data were obtained in 1994, one year prior to implementation of the program, and were re-evaluated in 1995 and 1998. Cost avoidance from utilization of epoetin alpha vial overfill in 1995 and 1998 was $83,560 and $91,148 respectively. In 1995 and 1998, cost avoidance from pharmacy management of anemia was $191,159 and $203,985 respectively. The total cost avoidance from 1995 through 1998 was estimated at $1,018,638. The number of patients with hematocrits under 31% decreased from 32% in 1994 to 21% and 14% in 1995 and 1998 respectively. We conclude that a pharmacy-managed anemia program for hemodialysis patients results in significant cost savings and better achievement of target hematocrits.


Author(s):  
P Frémaux ◽  
A Fiedler ◽  
J Lelievre ◽  
M Le Bot ◽  
V Cogulet

1995 ◽  
Vol 3 (3) ◽  
pp. 219-231 ◽  
Author(s):  
John R. Glowa ◽  
Francis H. E. Wojnicki ◽  
Dorota Matecka ◽  
John D. Bacher ◽  
Robert S. Mansbach ◽  
...  
Keyword(s):  

2021 ◽  
pp. 1-15
Author(s):  
Usha Luckock ◽  
Joanna Harnett ◽  
Rose Cairns

ABSTRACT Vitamin and mineral supplements (VMS) are widely available and commonly used. Little is known about patterns of poisoning exposures to VMS in the Australian population. We performed a retrospective study of calls to the New South Wales Poisons Information Centre (NSWPIC), July 2014-June 2019. NSWPIC is Australia’s largest PIC, taking approximately 100,000 calls/year (50% of Australian poisoning calls) from healthcare professionals and members of the public. We conducted additional analyses on iron exposures due to their high risk of acute toxicity. There were 10 944 VMS exposures reported to NSWPIC during the study period, increasing 9.6% per annum over a five year period (95%CI, 7.2 – 12.1%). Toddlers (1-4 years) accounted for 41.5% (4546) of cases. Agents most commonly involved were multivitamins (n=3610), Vitamin D (n=2080), iron (n=1533), and magnesium (n=804). In 17.7% (1934) of cases the call originated from hospital or the patient was referred to hospital by NSWPIC. Iron exposures increased by 14.0% per year (95%CI, 9.5 – 18.5%), and most were associated with high strength products (>45 mg elemental iron per unit dose, n=1036). Iron exposures were hospitalised in 38% of cases (n=583). We conclude that vitamin and mineral supplement exposures are increasing in Australia. Although most exposures can be managed at home, many required hospitalisation. Iron exposures are increasing and had higher rates of hospitalisation than other agents. Vitamin and mineral supplements are often considered safe and without the potential for adverse effects, highlighting the importance of public education into the potential risks of misuse of these products.


2021 ◽  
Keyword(s):  

Die COVID-19-Pandemie zeigt, dass sich Deutschland auf seine Krankenhäuser verlassen kann. Gut ausgebildete, leistungsbereite Mitarbeitende geben alles, um durch kreativen, agilen Einsatz Schlimmeres zu verhindern. Deutlich wird jedoch, dass Engagement und Kreativität nicht immer ausreichen. Das gilt z.B. für das Finden freier Intensivkapazitäten. Zwar kommen hier bereits digitale Lösungen zum Einsatz (z.B. das DIVI-Register) – nicht zuletzt führen jedoch uneinheitliche Datengrundlagen, basierend auf z.T. noch händischen Meldeprozessen, zu Effizienzeinbußen und Ungenauigkeiten. Der Mangel an digitalen Strukturen in deutschen Krankenhäusern tritt erneut zutage. Die Pandemie hält ein Brennglas auf die insuffiziente Digitalisierung im stationären Sektor; die Motivation zu einem mutigen Schritt in die Digitalisierung sollte aber nicht ausschließlich in der Bekämpfung von COVID-19 begründet sein. Hoffnung gibt das Krankenhauszukunftsgesetz (KHZG): Ausgestattet mit zusätzlichen Mitteln von 4,3 Mrd. Euro und klaren Vorgaben in 10 digitalen Handlungsfeldern schafft es die Grundlage, um bestehende digitale Defizite zu beheben. Vom Patientenportal über Unit-Dose-Medikamentierung bis zur Pflegedokumentation – die Förderrichtlinie kombiniert klare Vorgaben bezüglich Interoperabilität und Datensicherheit mit anwendungsbezogenen Muss-Kriterien. Im Vordergrund steht die strukturierte Digitalisierung patientennaher Arbeitsabläufe. Ein Weckruf für alle Beteiligten, unverzüglich diffuse Strategie in gestaltende Planung und Umsetzung zu überführen. Dieses Buch unterstützt Entscheider:innen und Anwender:innen bei der Gestaltung der Digitalisierung in den zentralen Handlungsfeldern. Die Digitalisierung wird praxisnah aus der Welt der IT-Nerds in den Planungs- und Entscheidungsalltag von Manager:innen, Ärzt:innen und Pflegenden überführt. Ein Muss für alle, die ihr Krankenhaus verantwortungsbewusst in die digitalisierte Zukunft führen wollen.


1976 ◽  
Vol 33 (12) ◽  
pp. 1254-1259
Author(s):  
Bruce Weiner ◽  
David J. McNeely ◽  
Ronica M. Kluge ◽  
Ronald B. Stewart
Keyword(s):  

2022 ◽  
Vol In Press (In Press) ◽  
Author(s):  
Sajad Moradi ◽  
Dinyar Khazaeli ◽  
Mohammadreza Dadfar ◽  
Nima Bakhtiari

Background: We aimed to evaluate the safety and efficacy of 50-unit dose against 100-unit dose of intracavernosal injection (ICI) of AbobotulinumtoxinA (BTX-A) (Masport®) in patients with vascular erectile dysfunction (ED) resistant to first-line therapies, including phosphodiesterase type 5 inhibitors (PDE5I). Methods: In this double-blind randomized controlled trial (RCT), 40 patients with ED resistant to PDE5I were randomly divided into two groups: ICI of a single dose of Masport® 50 units and single dose of 100 units. Peak systolic velocity (PSV) confirmed arterial insufficiency vascular disorder. For all patients, IIEF (International Index of Erectile Function), SHIM (Sexual Health Inventory for Men), and EHS (Erection Hardness Score) questionnaires were completed. Six weeks after the treatment, the subjects were re-examined. Results: Our results showed an acceptable clinical efficacy and safety of ICI of Masport® six weeks after injection. No systemic complications in patients were seen. Three patients complained of brief penile pain shortly after injection, but there were no other local complications. The increase in mean PSV in the 100-unit group due to treatment was significant (P-value < 0.0001). Also, there was a significant difference between the two groups of 50- and 100-unit (P-value < 0.0001). In addition, the increase in mean IIEF-EF, SHIM score, and EHS due to treatment was significant between the two groups. For the 100-unit group, P-value < 0.0001 and the difference between the two groups was also significant (P-value < 0.0001), which indicated a better response to treatment in the 100-unit group. The mean increase of IIEF score (EF domain) was 4.3 (mean IIEF: 9.4 and 13.7 after and before, respectively) in the 100-unit group and (mean IIEF: 8.1 and 9.1 after and before, respectively) in the 50-unit group. Conclusions: The results of this study showed that ICI of AbobotulinumtoxinA, especially at a dose of 100 units, in patients with refractory vasculogenic ED is safe and effective in improving sexual function and ultrasound indices.


2020 ◽  
Author(s):  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document